The EU pharmaceutical regulatory body has said it needs more time to complete a review intro controversial diabetes drug Avandia.
The European Medicine Agency (EMA) Committee for Medicinal Products For Human Use said new data had become available which it needed to assess.
The review is looking into data on the risk of cardiovascular problems relating to the Avandia (rosiglitazone) range of products and the drug’s benefits.
It is also considering the drug being sold in combination with metformin (Avandamet) and with glimepiride (Avaglim).
As part of the review, the committee has spoken to patients as well as experts in diabetes, cardiovascular diseases and pharmacovigilance.
The committee now said it hoped to finalise its findings by September, it said.
Copyright Press Association 2010